This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
South Korea
Abxign Inc. is a therapeutic antibody discovery company which focuses on the development of novel antibodies. Company offers therapeutics in the areas of oncology, cardiovascular, and autoimmune diseases.
AngioLab, Inc. is engaged in the discovery, development, and commercialization of anti-angiogenic candidates to inhibit abnormal new blood vessel growth associated with disease. AngioLab has various anti-angiogenic products candidates including herbal medicines, synthetic compounds and recombinant proteins.
AnyGen is a bio-venture company which focuses on manufacturing custom-made peptides and catalog peptides. They are also active in new drug development.
Aprogen, Inc. develops generic antibody drugs for treatment of rheumatoid arthritis. The company provides technological services to related domestic and international corporations and institutes.
B&C Biopharm is bio-pharmaceutical company focused on the drug discovery for the treatment of infectious and metabolic diseases. The company mainly focuses on diseases such as Hepatitis C Virus (HCV), Alzheimer?s disease, Tuberculosis and Osteoporosis.
BINEX is a biopharmaceutical company with GMP compliant manufacturing facility and actively seeking for in-licensing opportunities of biologic products. It plays the key role in solving the manufacturing bottleneck of biopharmaceutical industry with its hands-on experience on most blockbuster biologics (including biosimilar) and a top-notch biomanufacturing facility in compliance with the US and EU-GMP regulations. BINEX supply Remicade biosimilar to Sanofi Japan and Aprogen for clinical trials and commercialization products in Japan. It was able to acquire the commercialization right for a few biosimilars of blockbuster biologic products (Enbrel, Remicade, etc.) from business partners in return of providing a reliable and high quality CDMO services for products. Through collaboration with domestic and global partners,BINEX is looking for opportunities to license in and commercialize biologic products to expand its pipeline.
Bio-Synectics is a biopharmaceutical company pioneering new frontiers in delivery systems utilizing its nanoparticles technology. Based on its proprietary platform technologies Bio-Synectics provides specialist delivery solutions for poorly soluble substances.
Celltrion, Inc. is a Korea-based company principally engaged
in the development and manufacturing of protein drugs. The
Company operates its business under two segments. The
Biosimilar segment develops and manufactures biosimilar
products used to treat breast cancer, rheumatoid arthritis
disease, Crohn's disease, Hodgkin's lymphoma, colorectal
cancer, rheumatoid arthritis, respiratory syncytial virus, colon
cancer and others. The New Biopharmaceutical Development
segment is engaged in the development of
biopharmaceuticals, such as monoclonal antibodies against
rabies and breast cancers, pandemics and seasonal influenza viruses, through co-development with multinational
pharmaceutical and biotechnology companies.
in the development and manufacturing of protein drugs. The
Company operates its business under two segments. The
Biosimilar segment develops and manufactures biosimilar
products used to treat breast cancer, rheumatoid arthritis
disease, Crohn's disease, Hodgkin's lymphoma, colorectal
cancer, rheumatoid arthritis, respiratory syncytial virus, colon
cancer and others. The New Biopharmaceutical Development
segment is engaged in the development of
biopharmaceuticals, such as monoclonal antibodies against
rabies and breast cancers, pandemics and seasonal influenza viruses, through co-development with multinational
pharmaceutical and biotechnology companies.
CreaGene, Inc. is engaged in the development of prophylactic and therapeutic bio-medicine against diseases like cancer and autoimmune diseases. The company possesses a key-based technology for dendritic cells used in development of cancer therapeutic, cell drug delivery technology (CTP: Cytoplasmic Transduction Peptide) to effectively deliver polymeric substance to cell
Company's lead product CreaVax-RCC Inj. is indicated for the treatment of metastatic renal cell carcinoma.
Company's lead product CreaVax-RCC Inj. is indicated for the treatment of metastatic renal cell carcinoma.
Dai Han Pharm. Co., Ltd. is involved in pharmaceutical, manufacturing and supplying more than 200 medicinal products.
EyeGene, Inc., a South Korea based clinical stage biopharmaceutical, was established in 2000 focusing on ocular diseases and vaccines. Eyegene is located in Metropolitan Seoul with 30 full-time masters/doctoral level researchers and administrative staff.
Development status of lead candidates: EG-Mirotin (diabetic retinopathy, EU, Phase I), EG-HPV (HPV Vaccine, Korea, Phase I), EG-Decorin (pressure ulcer/bedsore, Korea, Phase I/II).
EG-Mirotin (therapeutic agent for diabetic retinopathy) completed pre-clinical trials in Europe/Korea and is currently in EU Phase I trials. They are looking for licensing partners for global territorial rights.
EG-HPV and EG-Decorin?s domestic territorial rights have been licensed out to CKD Pharma and Huons respectively (both are leading pharmaceutical companies in Korea). They are actively looking for licensing partners for global regions ex-Korea.
Development status of lead candidates: EG-Mirotin (diabetic retinopathy, EU, Phase I), EG-HPV (HPV Vaccine, Korea, Phase I), EG-Decorin (pressure ulcer/bedsore, Korea, Phase I/II).
EG-Mirotin (therapeutic agent for diabetic retinopathy) completed pre-clinical trials in Europe/Korea and is currently in EU Phase I trials. They are looking for licensing partners for global territorial rights.
EG-HPV and EG-Decorin?s domestic territorial rights have been licensed out to CKD Pharma and Huons respectively (both are leading pharmaceutical companies in Korea). They are actively looking for licensing partners for global regions ex-Korea.